An independent data monitoring committee has stopped a Phase III trial of a schizophrenia drug developed by Janssen early after the treatment showed statistically significant results in delaying the time to relapse, the Johnson & Johnson subsidiary said Thursday.
The international, randomized and double-blind study evaluated a three-month formulation of paliperidone palmitate in patients whose schizophrenia had appeared more than one year prior to the start date of April 2012.
A one-month formulation of the drug is already approved by the FDA as a maintenance treatment of schizophrenia.
Janssen hopes that a final analysis of study results, along with discussions with the FDA, will support a late-2014 NDA submission. — Lena Freund
Subscribe to Drug Industry Daily for complete coverage of the pharmaceutical industry. Click here for more information.